Immunotherapy and cytokines

Seminars in Veterinary Medicine and Surgery-Small Animal

Volumn 12, Issue 3, 1997, Pages 186-192

  Van Kampen, Kent R ^a  

^a Van Kampen Group Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; IMMUNOLOGICAL ADJUVANT;

ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; CAT; CAT DISEASE; DOG; DOG DISEASE; DRUG EFFECT; HORSE; HORSE DISEASE; IMMUNE SYSTEM; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; PHYSIOLOGY; PYODERMA; RESPIRATORY TRACT DISEASE; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CAT DISEASES; CATS; CYTOKINES; DOG DISEASES; DOGS; HORSE DISEASES; HORSES; IMMUNE SYSTEM; IMMUNOTHERAPY; PYODERMA; RESPIRATORY TRACT DISEASES;

EID: 0031203144     PISSN: 08820511     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-2867(97)80032-1     Document Type: Article

References (25)

1. Van Kampen KR: Part IV, pharmacology, section on nonspecific immunotherapy, in Fraser CM (ed): The Merck Veterinary Manual (ed 7). Rahway, NJ, Merck & Company, pp 1520-1521
2. Asnis LA, Gaspari AA: Cutaneous reactions to recombinant cytokine therapy. J Am Acad Dermatol 33:393-410, 1995
3. McHugh S, Deighton J, Rifkin I, Ewan P: Kinetics and functional implications of Th1 and Th2 cytokine production following activation of peripheral blood mononuclear cells in primary culture. Eur J Immunol 26:1260-1265, 1996
4. Kleinschuster SJ, Rapp HJ, Green KR, et al: Efficacy of intratumorally administered Mycobacterial cell walls in the treatment of cattle with ocular carcinoma. J Natl Cancer Inst 76:1165-1171, 1981
5. Comack S, Alkemade S, Rogan D: Clinical study evaluating a purified mycobacterial cell wall extract for the treatment of equine respiratory disease. Equine Practice 13:8, 1991
6. Viel L, Kenney D: Suspected adverse pulmonary reactions to Equimmune IV in four horses presented to the Ontario Veterinary College. Respiratory Conference, Philadelphia, PA, University of Pennsylvania, 1993 (abstr)
7. Becker AM, Janik TA, Smith EK, et al: Propionibacterium acnes immunotherapy in chronic recurrent canine pyoderma. An adjunct to antibiotic therapy. J Vet Intern Med 3:26-30, 1989
8. Cox WI: Examining the immunological and hematopoietic properties of an immunostimulant. Vet Med 83:424-428, 1988
9. Evans DR, Rollins JB, Huff GK, et al: Inactivated Propionibacterium acnes (ImmunoRegulin) as adjunct to conventional therapy in the treatment of equine respiratory disease. Equine Practice 10:17-20, 1988
10. Vail CD, Nestved AJ, Rollins JB, et al: Adjunct treatment of equine respiratory disease complex (ERDC) with the Propionibacterium acnes immunostimulant (EqStim). Equine Vet Sci 10:399-404, 1990
11. Hall H, Teucher C, Urie P, et al: Induced regression of bovine papillomas by intralesional immunotherapy. Ther Immunol 1:319-324, 1994
12. Platt GW: Osteomyelitis associated with founder - A unique approach. Veterinary Forum, May: 9, 1987
13. Nestved A: Evaluation of an immunostimulant in preventing shipping related respiratory disease. J Equine Vet Sci 16:78-82, 1996
14. DeBoer DJ: Strategies for management of recurrent pyoderma in dogs. Vet Clin North Am: Small Animal Practice 20:1509-1524, 1990
15. DeBoer DJ, Moriello KA, Thomas CB, et al: Evaluation of a commercial staphylococcal bacterin for management of idiopathic recurrent superficial pyoderma in dogs. Am J Vet Res 51:636-639, 1990
16. Esber HJ, DeCourcy SJ Jr, Bogden AE: Specific and nonspecific immune resistance enhancing activity of Staphage lysate. J Immunopharmacol 3:79-92, 1981
17. Morales CA, Schultz KT, DeBoer DJ: Antistaphylococcal antibodies in dogs with recurrent staphylococcal pyoderma. Vet Immunol Immunopathol 42:137-147, 1994
18. Harris C, Pierce K, King G, et al: Efficacy of Acemannan in treatment of canine and feline spontaneous neoplasms. Mol Biother 3:207-213, 1991
19. Swaim SF, Riddell KP, McGuire JA: The effects of Acemannan on wound healing models in the dog. European Tissue Repair Society and Wound Healing Society, Amsterdam, Netherlands, August 1993 (abstr 63)
20. Tizard IR, Kemp MC: Systemic macrophage stimulation results in accelerated wound healing. European Tissue Repair and Wound Healing Society, Oxford, England, August 1993 (abstr 48)
21. Vasko KA, McMichael J: Anti-inflammatory effects of an immuno-modulating agent. J Eq Vet Sci 8:77, 1988
22. Vasko KA, McMichael J, Smith B, et al: Use of an immuno-modulating agent in the treatment of myofasial pain. Vet Rev 8:5, 1988
23. Sheets MA, Unger BA, Giggleman GF Jr, et al: Studies of the effect of Acemannan on retrovirus infections: Clinical stabilization of feline leukemia virus infected cats. Mol Biother 3:41-45, 1991
24. Yates KM, Rosenberg LJ, Harris CK, et al: Pilot study of the effect of Acemannan in cats infected with feline immunodeficiency virus. Vet Immunol Immunopathol 35:177-189, 1992
25. Fogelman RW, Chapdelaine JM, Carpenter RH: Toxicologic evaluation of injectable Acemannan in the mouse, rat, and dog. Vet Hum Toxicol 34:201-205, 1992